Compass Therapeutics Inc (CMPX) concluded trading on Wednesday at a closing price of $1.69, with 5.69 million shares of worth about $9.62 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.15% during that period and on April 03, 2025 the price saw a loss of about -24.55%. Currently the company’s common shares owned by public are about 137.82M shares, out of which, 80.70M shares are available for trading.
Stock saw a price change of -17.16% in past 5 days and over the past one month there was a price change of -39.21%. Year-to-date (YTD), CMPX shares are showing a performance of 16.55% which decreased to -8.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.76 but also hit the highest price of $4.08 during that period. The average intraday trading volume for Compass Therapeutics Inc shares is 1.92 million. The stock is currently trading -25.90% below its 20-day simple moving average (SMA20), while that difference is down -39.53% for SMA50 and it goes to -6.26% lower than SMA200.
Compass Therapeutics Inc (NASDAQ: CMPX) currently have 137.82M outstanding shares and institutions hold larger chunk of about 38.86% of that.
The stock has a current market capitalization of $233.70M and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$0.36 in the same period. It has Quick Ratio of 14.96 while making debt-to-equity ratio of 0.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CMPX, volatility over the week remained 28.30% while standing at 12.66% over the month.
Analysts are in expectations that Compass Therapeutics Inc (CMPX) stock would likely to be making an EPS of -0.11 in the current quarter, while forecast for next quarter EPS is -0.12 and it is -0.49 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.15 which is -0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.08 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -30.00% while it is estimated to decrease by -14.10% in next year. EPS is likely to grow at an annualized rate of 23.33% for next 5-years, compared to annual growth of -104.70% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 02, 2025 offering an Outperform rating for the stock and assigned a target price of $6 to it. Coverage by Guggenheim stated Compass Therapeutics Inc (CMPX) stock as a Buy in their note to investors on February 24, 2025, suggesting a price target of $12 for the stock. On February 19, 2025, Piper Sandler Initiated their recommendations, while on December 23, 2024, D. Boral Capital Initiated their ratings for the stock with a price target of $32. Stock get a Market perform rating from Leerink Partners on November 15, 2024.
